What type of study is this?

September 12, 2025

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Key Points

Significant ADCC was observed only in TROP2-positive endometrial cancer cell lines.
Evaluated three endometrial cancer cell lines, with ADCC measured in the presence of PBMCs.
Datopotamab deruxtecan demonstrates potential as an effective treatment for TROP2-targeted endometrial cancers.
Results indicate the importance of TROP2 expression for the efficacy of antibody-drug conjugates.

Abstract

ADCC results of Dato-DXd, CTL-ADC, datopotamab, and rituximab (anti-CD20) in three representative endometrial cancer cell lines (A) END(K)34 TROP2-negative cell line, (B) END(K)254 TROP2 3+ cell line, and (C) END(K)265 TROP2 3+ cell line in the presence of PBMCs. Significant ADCC was detectable only against the TROP2-positive cell lines (B and C; *, P

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Santin et al. (Thu,) studied this question.

www.synapsesocial.com/papers/68d44b3031b076d99fa54926 — DOI: https://doi.org/10.1158/2767-9764.30102512

Authors

Niccolò G. Santin

Namrata Sethi

Stefania Bellone

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Actions

References and Citations

Citation Network

Connected Papers

Discussion